For example, intravenously administered LNDs demonstrated superior tumor penetration efficacy over liposomes, enabling the vast majority of tumor cells to be exposed to the STING agonist, thereby triggering robust T-cell activation and effective rejection of established tumors [35]. The gene discussed is STING1; the disease is neoplasm.